FierceBiotech met with three of the executives--John Knopf, founder and CEO, Tracey Murphy, senior director of corporate development, and Steven Ertel, the chief business officer--behind Acceleron's business strategy. The company targets epo-resistant anemias and does so through trials with a straightforward endpoint: counting red blood cells. There is a huge unmet need for anemic patients. Currently the only approved treatment is transfusions, which eventually leads to iron overload, which can be fatal. This is the first new treatment for anemia in 40 years, and the market potential is huge. Knopf told us that Acceleron is focused this year on more partnerships and collaborations--it already is partnered with Celgene, Shire (it is excited for the long-term potential of a program for DMD) and Alkermes--as it is solidly funded and has several promising products in its pipeline.